Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma Ltd, a clinical-stage biopharmaceutical company, is advancing its pipeline of small molecule therapeutic products targeting cancer, liver and inflammatory diseases, and erectile dysfunction. With a focus on the A3 adenosine receptor as a therapeutic target, the company is developing drugs for significant market opportunities, including a forecasted $11.3 billion psoriasis drug market by 2025. Despite promising prospects, the company cautions about forward-looking statements due to various risks, including financial uncertainties and the competitive nature of the biopharmaceutical industry.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
